This webinar presents a microfluidic ELISA technology for rapid (<15 min), quantitative, sensitive detection of SARS-CoV-2 S1 specific IgG in human serum. We also characterized various humanized monoclonal IgG and identified a candidate, D006, which has a high binding affinity and a relatively high specificity towards SARS-CoV-2 S1 protein that can serve as the calibration standard of anti-SARS-CoV-2 S1 IgG in serological analyses. With the aforementioned technology, we demonstrated that we were able to identify the best donor candidate for the convalescent plasma therapy, with a tiny drop of blood sample (<8 µL) and a fixed dilution factor (200 X). In addition, we also demonstrated that our microfluidic ELISA technology can sensitively detect SARS-CoV-2 antigens (S1 and N proteins) with LLODs at ~10 pg/mL in <40 minutes. Therefore, our technology will greatly facilitate rapid and quantitative analysis of COVID-19 related markers for both therapeutic and diagnostic purposes.
Vendor Website